Multidimensional assessment of urinary dysfunction and quality of life after cervical cancer treatment: a multicenter study integrating urodynamics and patient-reported outcomes

• by Krzysztof Bereza, Andrzej Kukiełka, Dominika Trojnarska, Beniamin Oskar Grabarek, Marcin Opławski, Tomasz Banaś

• July 2, 2026

ASCO26: Jennifer Ligibel, MD, BWEL

Dana-Farber Cancer Institute's Dr. Jennifer Ligibel shared updated results from the BWEL study showing a weight loss intervention led to significantly better physical function, global physical and mental health, and symptom in patients with early breast cancer.

• July 1, 2026

• 1 min

ASCO26: Toni Choueiri, MD, KEYNOTE-654

Data highlights limitations of ctDNA assay used to predict outcomes in participants with renal cell carcinoma treated with adjuvant pembrolizumab in the KEYNOTE-564 trial. Dana-Farber Cancer Institute's Dr. Toni Choueiri explains that ctDNA+ was associated with worse disease-free outcomes, but sensitivity was low.

• July 1, 2026

• 1 min

Prediction of histological grading in ductal carcinoma in situ based on mammographic signs and clinical information using machine learning models

• by Jianyu Wang, Shilu Zhao, Liuying Zhao, Furong Huang, Hao Wu, Da Pang

• July 2, 2026